absence seizures

临床试验

计划入组 5 人 · 首次发布于 2009 年 4 月 20 日

已完成

NCT04899050

Epidiolex in Typical Absence Seizures

计划入组 14 人 · 首次发布于 2021 年 5 月 24 日

已完成

NCT03406702

CX-8998 for Absence Seizures

计划入组 7 人 · 首次发布于 2018 年 1 月 23 日

药物

查看全部 39 →

Small Molecule

Approved

Methsuximide(Celontin)

相关疾病：Refractory absence Seizures

C₁₂H₁₃NO₂

Small Molecule

Approved

Valproic acid(Depakene, Depakote, Epival)

生产企业：Banner pharmacaps inc, Abbott laboratories pharmaceutical products div，另有 12 家

相关疾病：Bipolar Disorder (BD), Complex Partial Seizure Disorder，另有 5 项

C₈H₁₆O₂

Small Molecule

Approved

Phenobarbital(Donnatal, Luminal, Phenobarb, Phenohytro, Sezaby)

相关疾病：Alcohol Withdrawal Syndrome, Anxiety，另有 7 项

C₁₂H₁₂N₂O₃ · Rx

机构

查看全部 5 →

BARIJ ESSENCE COMPANY

Iran

ESSENCE BIOTECH PTY LTD

Australia

BARIJ ESSENCE PHARMACEUTICAL COMPANY

Iran

资讯

查看全部 3385 →

8个月前

Bright Minds Biosciences Set to Release Phase 2 Results for BMB-101 in Drug-Resistant Epilepsy

去年

Lundbeck's Bexicaserin Shows Sustained 59% Seizure Reduction in Rare Epilepsy Extension Study

去年

临床试验

Magnetoencephalography in Absence Seizures

Epidiolex in Typical Absence Seizures

CX-8998 for Absence Seizures

药物

Methsuximide(Celontin)

Valproic acid(Depakene, Depakote, Epival)

Phenobarbital(Donnatal, Luminal, Phenobarb, Phenohytro, Sezaby)

机构

BARIJ ESSENCE COMPANY

ESSENCE BIOTECH PTY LTD

BARIJ ESSENCE PHARMACEUTICAL COMPANY

资讯

Bright Minds Biosciences Set to Release Phase 2 Results for BMB-101 in Drug-Resistant Epilepsy

Lundbeck's Bexicaserin Shows Sustained 59% Seizure Reduction in Rare Epilepsy Extension Study

Epilepsy Drug Pipeline Shows Robust Growth with 90+ Therapies in Development Across 75+ Companies